Cyrille T.
- Country
- France
- Department
- Hematologie clinique
Research Overview
- Pharmacokinetic Comparability Study of Pre- and Post-change Teclistamab in Relapsed/Refractory Multiple Myeloma Patients
- Dose Optimization and Safety Evaluation of ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma
- Phase 1b Evaluation of Bispecific T Cell Redirection Antibodies with Checkpoint Inhibitors in Relapsed/Refractory Multiple Myeloma Patients
Data & Insights
Has run more than one trial at 306 of 488 partner sites.
Specializations
Multiple Myeloma Treatment
Specializes in investigating novel therapeutic approaches for multiple myeloma, with particular emphasis on treatment strategies for both newly diagnosed and relapsed/refractory cases.
- Bispecific antibody therapies
- Immunotherapy combinations
- Cell-based treatments
Conducts extensive research on innovative drug combinations and maintenance therapies for enhanced treatment outcomes.
Specialized Hematologic Conditions
Focuses on complex blood disorders including plasma cell leukemia and AL amyloidosis, with particular attention to treatment-resistant cases.
- High-risk disease management
- Stem cell transplantation
- Minimal residual disease assessment
Develops targeted approaches for specific patient populations including elderly and transplant-ineligible patients.
Treatment Innovation
Leads investigations into novel therapeutic agents and their combinations, focusing on improving response rates and patient outcomes.
- Antibody-based therapies
- Combination treatment strategies
- Response optimization protocols
Evaluates emerging treatments across various stages of multiple myeloma progression.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.